Company news

Eloxx Pharmaceuticals, Inc. news in 2026

Eloxx Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference

November 2, 2026

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

October 29, 2026

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

October 20, 2026

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

October 19, 2026

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

September 11, 2026

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

ELOX: Q1 2026 net loss rose to $3.8M, cash insufficient for 12 months, all debt eliminated via equity

May 5, 2026

ELOX: Sixth Amendment adds bridge and Tranche 2 loans, PIK interest, and new agent SD MF 4 LLC

March 17, 2026

Decks in 2026